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Abstract 
Human γδ T cells display potent responses to pathogens and malignancies. Of particular 
interest are those expressing a γδ T cell receptor (TCR) incorporating TCRδ-chain variable-
region-2 (Vδ2(+) T cells), that are activated by pathogen-derived phosphoantigens (pAgs), or 
host-derived pAgs that accumulate in transformed cells or in cells exposed to 
aminobisphosphonates. Once activated, Vδ2(+) T cells exhibit multiple effector functions that 
have made them attractive candidates for immunotherapy. Despite this, clinical trials have 
reported mixed patient responses, highlighting a need for better understanding of Vδ2(+) T 
cell biology. Here, we reveal previously unappreciated functional heterogeneity between the 
Vδ2(+) T cell compartments of 63 healthy individuals. In this cohort, we identify distinct “Vδ2-
profiles” that are stable over time, that do not correlate with age, gender, or history of 
phosphoantigen activation, and that develop after leaving the thymus. Multiple analyses 
suggest these Vδ2-profiles consist of variable proportions of two dominant but contrasting 
Vδ2(+) T cell subsets that have divergent transcriptional programs and that display 
mechanistically distinct cytotoxic potentials. Importantly, an individual’s Vδ2-profile predicts 
defined effector capacities, demonstrated by contrasting mechanisms and efficiencies of 
killing of a range of tumour cell lines. In short, these data support patient stratification to 
identify individuals with Vδ2-profiles that have effector mechanisms compatible with tumour 
killing, and suggest that tailored Vδ2-profile-specific activation protocols may maximise the 
chances of future treatment success. 
Keywords: Human γδ T cells; Vδ2(+) T cells; anti-tumour cytotoxicity; functional 
heterogeneity 
Significance Statement 
A type of human white blood cell, known as the Vδ2(+) T cell, has shown promise in 
immunotherapies against a range of tumours. However, in recent clinical trials patient 
responses and clinical outcomes have been variable and unpredictable. To address this, we 
here reveal a significant variability in Vδ2(+) T cell functional potential between individuals in 
the general population, which develops shortly after birth, is stable over time, and is manifest 
by differential mechanistic capacities to kill tumour targets. These results support 
personalised clinical approaches to identify patients with “Vδ2-profiles” that are compatible 
with killing of their particular tumour, and suggest that tailored Vδ2-profile-specific activation 
protocols may maximise the chances of future treatment success.  
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Introduction 
Human γδ T cells display potent responses to pathogens and malignancies (1-3). Of 
particular interest are those that express TCRδ-chain variable-region-2 (Vδ2(+) T cells) (4). 
These cells are uniquely activated by low-molecular-weight non-peptide phosphoantigens 
(pAgs), such as microbial-derived (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-
PP) (5, 6). Vδ2(+) T cells are also activated by isopentyl pyrophosphate (IPP), a pAg that 
accumulates in transformed eukaryotic cells, or cells exposed to aminobisphosphonates 
such as zoledronate (7). The mechanism of pAg-mediated activation of Vδ2(+) T cells is still 
unclear, but likely involves pAg association with butyrophilin 3A1 (BTN3A1) (8, 9). 
Consequent to pAg stimulation, Vδ2(+) T cells can display significant cytokine-dependent 
functional plasticity. Indeed, Th1-like, Th2-like, Th17-like, and Treg-like effector 
characteristics have all been reported (10-14). Moreover, Vδ2(+) T cells demonstrate efficient 
cytolytic capacity (15-17), and function as antigen presenting cells if activated under 
appropriate conditions (18). These functional potentials underpin the role of Vδ2(+) T cells in 
diverse immune scenarios. Vδ2(+) T cells respond vigorously to Mycobacterium tuberculosis 
(19) and Plasmodium falciparum (20), often expanding to >50% of total blood T cells (21), 
and show responses to both HIV (22) and influenza (23). Vδ2(+) T cells also kill a spectrum of 
malignant cells that includes leukaemias and lymphomas, and solid tumours such as renal 
cell, breast, prostate and colorectal carcinomas (24). Indeed, meta-analysis of gene 
expression signatures from ~18,000 human tumours across 39 malignancies indicated a 
tumour-associated γδ T cell profile as the best predicator of patient survival (25). Thus, there 
appears enormous potential to harness these anti-pathogen and anti-tumour effector 
functions for clinical applications. 
Despite this therapeutic promise, results from phase I/II clinical trials that have activated 
Vδ2(+) T cells with aminobisphosphonates are mixed. While objective clinical outcomes were 
observed in some patients with relapsed/refractory low-grade non-Hodgkin’s lymphoma, 
multiple myeloma, metastatic hormone-refractory prostate cancer or advanced metastatic 
breast cancer (26-28), numerous patients failed to demonstrate effective Vδ2(+) T cell 
responses. Clearly, understanding this person-to-person heterogeneity in Vδ2(+) T cell 
responsiveness, correlated with subsequent clinical outcome, is critical, not only for 
optimisation of Vδ2(+) T cell-related therapies, but also for predicting disease progression 
where Vδ2(+) T cell responses are involved. 
In this study, we reveal functional Vδ2(+) T cell heterogeneity, between individuals, in a large 
cohort of healthy volunteers. The effector potentials of these “Vδ2-profiles” are characterised 
by two dominant but qualitatively contrasting phenotypes. At one extreme, Vδ2(+) T cells 
display high proliferative capacity, express several cytokine and chemokine receptors, and 
demonstrate unusual granzyme K-mediated target cell killing. At the other extreme, Vδ2(+) T 
cells have lower expansion potential, but possess a dominantly cytotoxic nature 
characterized by granzyme B-mediated cytotoxicity. This inter-individual Vδ2(+) T cell 
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heterogeneity develops after birth, although acquisition of a particular Vδ2-profile does not 
correlate with gender, age, country of birth, or chronic Vδ2(+) T cell stimulation in vivo. 
Moreover, these Vδ2-profiles were stable in individuals over the three-year study period, 
suggesting an active homeostatic maintenance. Importantly, an individual’s Vδ2-profile 
predicts functional potential that we demonstrate by differential killing of various tumour cell 
lines. Thus, these data highlight a phenotypic and functional heterogeneity in the human 
Vδ2(+) T cell pool that has profound clinical implications, such that individuals with different 
Vδ2-profiles would be predicted to respond differently to Vδ2(+) T cell-targeted 
immunotherapies, or in response to infections. 
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Results 
Significant functional heterogeneity in Vδ2(+) T cell subsets between healthy 
individuals 
We had regularly observed phenotypic heterogeneity when using the commonly utilised 
markers CD27 and CD45RA to assess human Vδ2(+) T cells from small numbers of healthy 
volunteers (Fig. 1A). As this compromised our interpretation of Vδ2(+) T cell involvement in 
disease, the nature and extent of this heterogeneity was investigated in a much larger cohort 
of healthy individuals (n=63). In our hands, CD45RA staining of Vδ2(+) T cells (but not other T 
cell subsets) does not give distinct demarcation of positive and negative subsets (Fig. 1A). 
Thus, we instead assessed Vδ2(+) T cells using CD27, CD28 and CD16 that consistently 
identified four distinct Vδ2(+) populations; γδ(28+) cells [CD28(+)CD27(+)CD16(-)]; γδ(28-) cells 
[CD28(-)CD27(+)CD16(-)]; γδ(16-) cells [CD28(-)CD27(-)CD16(-)], and; γδ(16+) cells [CD28(-)CD27(-
)CD16(+)] (Fig. 1B). The γδ(28+) population was most prevalent across the cohort (Fig. 1C) 
comprising on average ~54% of total Vδ2(+) T cells, followed by the γδ(28-) subset (~22%), 
γδ(16+) subset (~11%) and γδ(16-) subset (~8%). However, dominance of a particular subset did 
not correlate with age, gender, or developmental index of country of birth (Fig. S1). The four 
Vδ2(+) T cell subsets were functionally assessed after stimulation with bisphosphonate 
(zoledronate) and IL-2. Proliferative potential segregated with CD27 expression, as the γδ(28+) 
and γδ(28-) subsets, but less so the γδ(16-) and γδ(16+) subsets, divided multiply after activation 
(Fig. 1D). Consistent with this, γδ(16+) cells expressed the highest level of CD57 that has been 
reported to correlate with replicative senescence (29), although other markers of exhaustion, 
such as PD-1, were similar across all populations (Fig. S2). All subsets had potential to 
secrete both IFNγ and TNFα (Fig. S3). However, cytolytic capacity, assessed by intracellular 
staining for perforin and granzyme B (Fig. 1E), and surface staining of CD56 (Fig. S4), was 
greater in the γδ(16-) and γδ(16+) subsets. Finally, the γδ(28+) subset demonstrated a reduced 
capacity to degranulate, judged by surface CD107a expression after 8hr of activation (Fig. 
1F). Thus, CD27, CD28, and CD16 unambiguously identify four subsets of Vδ2(+) T cells in 
normal healthy individuals. Importantly, as these subsets have distinct functional capacities, 
the overall effector potential of the Vδ2(+) T cell compartment will reflect the relative 
contributions of these subsets in any given individual. 
Individuals possess stable Vδ2-profiles  
The 63 healthy individuals could be stratified into six “Vδ2-profiles” defined by relative 
distribution of the γδ(28+), γδ(28-), γδ(16-), and γδ(16+) subsets (Fig. 2A), that also did not correlate 
with gender, with developmental index of country of birth, or as yet, with a limited 
assessment of ethnicity (Fig. S5). Profile #2 (50-70% γδ(28+) cells with 10-35% γδ(28-) cells) 
was observed most frequently (n=28), and only two profiles featured a single dominant 
subset; γδ(28+) cells were dominant in profile #1 whereas γδ(16+) cells dominated profile #6 
(Fig. 2A). This is consistent with γδ(28+) and γδ(16+) cells being at opposite ends of a 
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differentiation pathway, with γδ(28-) and γδ(16-) cells in-between. However, the prevalence of 
any particular profile (e.g. profile #6) did not increase with age (Fig. 2B), suggesting that 
regular and cumulative exposure to phosphoantigen-producing pathogens is not sufficient to 
drive differentiation of Vδ2(+) T cells from one subset phenotype to another. This stable 
nature of an individual’s Vδ2-profile over time was supported by a longitudinal analysis of 
Vδ2(+) T cells from three individuals over 36-months, in which each person’s Vδ2-profile 
remained largely constant (Fig. 2C). Moreover, analysis of blood from osteoporotic patients 
on long-term oral or intravenous bisphosphonates (essentially the chronic activation of Vδ2(+) 
T cells, in vivo), did not reveal a selective accumulation of any Vδ2(+) T cell subset or profile 
(Fig. 2D). In vitro, monitoring over 12-days of Vδ2(+) T cells after phosphoantigen/IL-2 
activation of PBMCs from healthy individuals demonstrated significant recovery of the initial 
Vδ2-profiles (Fig. S6). And even short-term stimulation of sorted Vδ2(+) T cell subsets by 
phosphoantigen/IL-2 for 3 days, in the presence of sorted CD14(+) autologous accessory 
cells, demonstrated little change to the initial Vδ2(+) T cell phenotypes (Fig. S7). Thus, the 
Vδ2(+) T cell compartments of normal healthy adult individuals can be stratified into distinct 
Vδ2-profiles, that are stable over time, and that do not essentially change in response to 
acute or chronic Vδ2(+) T cell activation. To investigate whether these Vδ2-profiles are “set” 
during early Vδ2(+) T cell development, Vδ2-profiles were assessed from ten neonatal (4-22 
months) thymuses obtained from cardiac surgeries. Only the CD28(+)CD27(+)CD16(-) 
phenotype of profile #1 was evident in all samples (Fig. 2E). Such initial uniformity of Vδ2(+) T 
cell phenotype suggests that the range of distinct Vδ2-profiles is established post-thymically, 
presumably in response to early interactions with the neonatal and/or infant environment. 
Vδ2-profiles are polarized towards two dominant phenotypes 
Each Vδ2-profile consists of different proportions of γδ(28+), γδ(28-), γδ(16-), and γδ(16+) cells, the 
combination of which will differentially dictate overall Vδ2(+) T cell responses. To explore 
these functional potentials further, we sorted γδ(28+), γδ(28-), γδ(16-), and γδ(16+) cells to high 
purity from three different individuals to perform microarray expression analysis (using 
Illumina’s HumanHT-12 v4 beadchip array). After multiple comparisons for genes expressed 
at least 2-fold higher or lower between any two subsets the γδ(28+) and γδ(16+) populations 
appeared most different (469 genes), consistent with these subsets having distinct functional 
potentials (Fig. 3A). By contrast, only 78 genes differed between γδ(28-) and γδ(16-) cells. 
We also re-analysed our flow cytometry data using Gemstone software that assesses 
multiple flow parameters from multiple flow cytometry data files simultaneously 
(http://www.vsh.com/products/gemstone/). This is used to order or group cells by phenotypic 
similarity. Using assumptions that CD27, CD28 and CD16 expression can be high or low on 
any cell, the software analysed all collected events from all 63 individuals to generate a 
summary representation of common cell phenotypes from all samples (Fig. 3B). This 
analysis supported the idea of dominant γδ(28+) and γδ(16+) subsets, and again suggested less 
well-defined distinctions between γδ(28-) and γδ(16-) cells with several additional intermediate 
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phenotypes. Taken together with our data indicating that Vδ2-profiles are stable over time, it 
suggests that the Vδ2(+) T cell compartments of healthy adult individuals are polarized, to 
different extents, toward one of two major effector potentials; dominated respectively by 
either the γδ(28+) or γδ(16+) subset. 
Demarcation of dominant Vδ2(+) T cell phenotypes by CCR6 and CX3CR1 
To explore Vδ2-profile effector potentials further, a table of immune-related genes that 
differed in expression by ≥2-fold between γδ(28+) and γδ(16+) cells was compiled (Fig. 3C). This 
highlighted differential expression in γδ(16+) cells of genes related to cytotoxic function, 
including perforin, granzyme B, granzyme H, granulysin, and eight members of the killer cell 
Ig-like receptor (KIR) family. By contrast, γδ(28+) cells expressed higher levels of granzyme K 
(30), and cytokine and chemokine receptors such as IL-7Rα, IL-18Rα, IL-23R, CCR2, CCR7, 
and CCR6 (see below). 
Of particular interest was differential expression of CCR6 in γδ(28+) cells (~4.4-fold higher), 
and CX3CR1 (fractalkine receptor) in γδ(16+) cells (~10-fold higher), which was validated in 12 
individuals (Fig. 4A). CX3CR1 was expressed at high levels by all γδ(16+) cells, but only by a 
fraction of the γδ(28+) subset, and at a lower per-cell level. Conversely, CCR6 was not 
detected on γδ(16+) cells, but identified a distinct population of CCR6(+)CX3CR1(-) γδ(28+) cells. 
An identifiable subset of CCR6(+)CX3CR1(+) double positive cells was never truly evident, 
suggesting a mutually exclusive relationship that may have functional implications. 
Consistent with this, the intensity of CX3CR1 expression correlated with cytolytic potential as 
judged by co-expression of granzyme B and perforin (Fig. 4B). By contrast, CCR6(+) γδ(28+) 
cells were GzmB(-)Pfn(-) but expressed granzyme K (Fig. 4C). CCR6(+) γδ(28+) cells also 
expressed higher surface levels of both CCR2 and CCR5 (Fig. 4D), and the IL-18Rα chain 
(Fig. 4E), compared with CX3CR1(+) cells. CCR6 and granzyme K were also expressed (in 
the absence of CX3CR1 and granzyme B), in a sizable proportion of Vδ2(+) T cells from all 
our neonatal thymus samples (Fig. 4F), supporting the idea that freshly generated Vδ2(+) T 
cells initially adopt a profile #1 phenotype. 
CCR6, along with RORγt and IL-23R that are also differentially up-regulated in γδ(28+) cells 
(Fig. 3C), are associated with an IL-17A-secreting phenotype (31, 32). Unlike in mice, 
human γδ cells with IL-17A-secreting potential are not abundant in adult peripheral blood 
(12). However, they are present in cord blood (33), and in inflammatory lesions of 
immunopathologies such as meningitis and psoriasis (12, 34); thus, their origin are of 
particular importance. As expected, very few IL-17A-secreting Vδ2(+) T cells were observed 
in peripheral blood of any individual tested. Nonetheless, when these cells were observed 
they expressed CCR6 (Fig. 4G) and resided in the γδ(28+) subset (Fig. S8). Moreover, 
CCR6(+) γδ(28+) cells expressed higher levels of CD161, the upregulation of which was 
recently demonstrated on IL-17A-secreting Vδ2(+) T cells in vitro (12) (Fig. 4H).  
RYAN	  et	  al	  
	   8	  
Distinct Vδ2-profiles display distinct cytotoxic effector potentials 
The data above predict that healthy adult individuals with distinct Vδ2-profiles will display 
qualitatively different effector responses to phosphoantigen challenge. To explore this, 
PBMC were isolated from individuals with either Vδ2-profile #1 or #2, in which γδ(28+) cells 
dominate, or Vδ2-profile #5 or #6, in which γδ(16+) cells dominate. As expected, total Vδ2(+) T 
cells from profiles #1/2 expanded on average >10-fold more than those from profiles #5/6 in 
response to HMB-PP/IL-2 (Fig. 5A). Next, we assessed cytotoxic potential by first 
confirming, in 5 further subjects, that Vδ2(+) T cells from profile #6 individuals express high 
levels of granzyme B and granulysin, whereas Vδ2(+) T cells from profile #1 individuals 
instead express granzyme K (Fig. 5B). Consistent with this contrast in cytotoxic potential, 
HMB-PP/IL-2-expanded Vδ2(+) T cell lines from profile #6 subjects efficiently lysed MOLT-4 
cells (acute lymphoblastic leukaemia), DOHH-2 cells (B cell lymphoma), and HL-60 cells 
(acute promyelocytic leukaemia), to a much greater extent than expanded Vδ2(+) T cell lines 
from profile #1 individuals (Fig. 5C). Nonetheless, Vδ2(+) T cell lines from both profiles 
efficiently killed Jurkat cells (acute T cell leukaemia), while Vδ2(+) T cell lines from profile #1 
individuals killed HCT-116 cells (colon carcinoma) more effectively than those from profile #6 
(Fig. 5C). HCT-116 cells are reported to express proteinase inhibitor 9 (PI-9), a potent 
inhibitor of granzyme B (but not granzyme K) (35), possibly explaining the reduced cell killing 
in profile #6 cultures. This differential killing was confirmed using sorted Vδ2(+) T cells from 
profile #1 and #6 individuals activated with HMB-PP/IL-2 for 4 hours and then co-cultured 
with HCT-116 cells (Fig. 5D). Importantly, the greater killing of HCT-116 cells in profile #1 
cultures could be inhibited by pre-incubation of the Vδ2(+) T cells with nafomostat mesylate 
(NM) that inhibits granzyme K (36) (Fig. 5D). NM also reduced killing of MOLT-4 cells by 
freshly isolated HMB-PP/IL-2-activated Vδ2(+) T cells from profile #1 individuals, whereas 
granzyme B inhibitor Z-Ala-Ala-Asp(OMe)-chloromethyl ketone (Z-AAD) (37) had minimal 
effect (Fig. 5E). Conversely however, Z-AAD, but not NM, was able to inhibit MOLT-4 cell 
killing in similar cultures of activated Vδ2(+) T cells from profile #6 individuals, confirming a 
granzyme B-mediated mode of cytotoxicity (Fig. 5E). Vδ2(+) T cells from profile #6 subjects 
also express abundant CD16 that can mediate antibody-dependent cellular cytotoxicity. 
Consistent with this, DAUDI cells (Burkitt’s Lymphoma) that are killed to some degree by the 
anti-CD20 antibody rituximab, show almost complete cell lysis in the presence of activated 
Vδ2(+) T cells from profile #6 individuals (Fig. 5F). By contrast, Vδ2(+) T cells from profile #1 
subjects in the presence of rituximab, and Vδ2(+) T cells from either profile in the absence of 
rituximab, displayed no significant DAUDI cell killing above control (Fig. 5F). In sum, our data 
demonstrate that individuals with distinct Vδ2-profiles display qualitatively distinct Vδ2(+) T 
cell-mediated cytotoxic effector function, that is mediated in large part by differential 
expression of cytotoxic mediators such as granzyme B and K. Importantly, this suggests that 
only individuals possessing Vδ2-profiles that are compatible with particular features of their 
tumour targets are likely to show promising clinical outcomes.   
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Discussion 
Current understanding of Vδ2(+) T cell biology does not adequately explain the variability in 
objective clinical responses in Vδ2(+) T cell-based immunotherapies against cancer (26-28). 
In addressing this, we demonstrate significant inter-individual heterogeneity in Vδ2(+) T cell 
phenotype that translates to distinct Vδ2(+) T cell effector potentials. Our analysis of 63 
healthy individuals revealed several “Vδ2-profiles”; each defined by differing proportions of 
Vδ2(+) T cell subsets with distinct functional characteristics. Using multiple analyses, our data 
suggest that these Vδ2-profiles consist of varying contributions from two dominant but 
contrasting Vδ2(+) T cell populations; identified as γδ(28+) and γδ(16+) cells. Moreover, these 
opposing phenotypes segregate by mutually exclusive expression of chemokine receptors 
CCR6 and CX3CR1. CX3CR1 correlates with increased granzyme B/perforin-associated 
cytotoxic capacity but decreased proliferative potential, whereas CCR6 characterises γδ(28+) 
cells with increased expression of cytokine receptors (e.g. IL-18Rα) and chemokine 
receptors (e.g. CCR2 and CCR5), and expression of granzyme K. CCR6(+) γδ(28+) cells also 
include the few IL-17A-secreting Vδ2(+) T cells found in peripheral blood.  
A key finding is that distinct Vδ2-profiles appear stable over time, as highlighted in three 
individuals over 36-months. It had been suggested from studies in vitro that phosphoantigen 
stimulation of Vδ2(+) T cells resulted in differentiation from a CD27(+)CD45RA(+) phenotype to 
either a CD27(-)CD45RA(-) or CD27(-)CD45RA(+) phenotype, via a CD27(+)CD45RA(-) 
intermediate (15). However, in our cohort, older individuals, who inevitably will have been 
exposed to more phosphoantigen-producing pathogens than younger individuals, did not 
favour any particular Vδ2-profile. Moreover, patients on long-term (>36 months) 
bisphosphonate therapies, either orally or intravenously, did not present with any specific 
Vδ2-profile, as would be expected if repeated stimulation drove Vδ2(+) T cell differentiation. 
Together, these findings suggest Vδ2-profiles change little over time despite repeated 
stimulation. This evokes a model in which Vδ2(+) T cell activation expands short-lived effector 
cells, but preserves proportions of longer-lived “memory” cells to maintain the Vδ2-profile. 
The underlying mechanism for this requires further investigation but may involve “memory 
stem cell” activity, akin to that described for memory CD8(+) αβ T cells (38), although whether 
Vδ2(+) T cells demonstrate true memory is still uncertain (39). 
The stable yet heterogeneous nature of Vδ2-profiles between healthy individuals raises the 
question of how they develop. The neonatal (4-22 months) thymus data demonstrate a 
uniformity of phenotype that resembles profile #1, with a predominance of γδ(28+) cells, and 
expression of CCR6 and granzyme K. This suggests that, presumably early in life (40), an 
individual’s Vδ2(+) T cell compartment transitions from a uniform thymic profile to a particular 
peripheral profile that constitutes a stable set-point. The drivers of this transition may be 
genetic. Alternatively, it may result from childhood exposure to specific pathogens, such as 
Mycobacterium tuberculosis (19), Plasmodium falciparum (20), or CMV (41). Such infections 
may cause aggressive, or qualitatively different, Vδ2(+) T cell responses that force a change 
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in Vδ2-profile. Such profile-changing responses could also depend on certain Vγ9Vδ2TCR 
specificities that are restricted to certain individuals. These ideas are currently under 
investigation. 
A corollary to identification of distinct stable Vδ2-profiles across healthy subjects is that these 
individuals should demonstrate distinct Vδ2(+) T cell-mediated effector responses. Indeed, we 
demonstrate differences in both efficiency and mechanism by which Vδ2(+) T cells, from 
profile #1 versus profile #6 individuals, kill a range of tumour lines. Profile #6 Vδ2(+) T cells 
show Granzyme B-mediated cytotoxicity, but are not efficient at killing tumour lines that 
express the Granzyme B inhibitor PI-9. However, these cells can additionally deploy ADCC 
to kill tumour targets in the presence of tumour-binding antibodies. By contrast, Vδ2(+) T cells 
from profile #1 individuals favour Granzyme K-mediated cytotoxicity, and appear more 
effective at killing PI-9(+) tumour cells than profile #6 Vδ2(+) T cells. These data thus have 
important clinical implications for patient stratification in Vδ2(+) T cell-based therapies, as 
there is likely an optimal Vδ2(+) T cell response for any given malignancy. Although the Vδ2(+) 
T cell compartment is in theory capable of making a range of responses, a particular patient 
may be restricted in the responses they can actually make. If this effector potential is 
mismatched to that required to target a particular tumour, treatment is likely to fail, which 
may have contributed to inconsistent patient responses in recent clinical trials (26-28, 42). 
By contrast, selecting patients with defined Vδ2(+) T cell effector potentials that complement 
features of a tumour, and tailoring activation protocols to optimise specific responses, may 
maximise the chances of future treatment success. 
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Materials and Methods 
Study population. Informed consent and ethical approval was obtained for blood (London - 
City and East Research Ethics Committee (REC) 13/LO/0548) and thymus samples (London 
- Queen Square REC 14/LO/2132).  
The isolation of peripheral blood mononuclear cells (PBMC), flow cytometry, proliferation 
assays, cytotoxicity assays, degranulation assay, Gemstone™ probability state modelling 
(PSM), microarray analysis, and statistical analyses are described in the SI Methods. 
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Figure legends 
Fig. 1. Inter-individual Vδ2(+) T cell phenotypic variation. (A) CD27/CD45RA plots of blood 
Vδ2(+) cells from 5 healthy individuals. Quadrant % are indicated. (B) Non-naïve CCR7(-) 
Vδ2(+) cells comprise 4 subsets; γδ (28+) [CD28(+)CD27(+)CD16(-)]; γδ(28-) [CD28(-)CD27(+)CD16(-
)]; γδ(16-) [CD28(-)CD27(-)CD16(-)], and; γδ(16+) [CD28(-)CD27(-)CD16(+)]. (C) Vδ2(+) subset 
distribution for 63 healthy individuals (mean +/- s.d.). (D) Representative plots of eFluor®670 
dilution in sorted Vδ2(+) subsets after culture with Vδ2-depleted mononuclear accessory cells 
(1:1) 7-days after stimulation with zoledronate (1µM) + IL-2 (100U/mL); proliferating cells (P), 
undivided cells (UD). (E) Intracellular Perforin and Granzyme B in Vδ2(+) subsets after 4h 
stimulation of PBMC ex-vivo with PMA/ionomycin. Summary chart for % of Vδ2(+) subset 
producing; Perforin (Pfn(+)), Granzyme B (GzmB(+)) or both (Pfn(+)GzmB(+)) (n=3). (F) MFI of 
CD107a on Vδ2(+) subsets 8h after activation of PBMCs with HMB-PP (20nM) + IL-2 
(100U/mL). Multiple comparison testing using one-way ANOVA with Tukey’s post-test used 
in E and F, *P < .05, **P < .01 and ***P < .001. 
Fig. 2. Healthy individuals have stable Vδ2-profiles. (A) Top rows: Representative individuals 
possess distinct Vδ2-profiles. Bottom charts: Individuals (n=63) were assigned to a Vδ2-
profile. (B) Chart of mean age (years) for Vδ2-profiles (#1 to #6). (C) Longitudinal analysis of 
Vδ2-profiles #3,  #4 and #6 at t=0 and 36-mths. (D) Plots of Vδ2-profiles from osteoporotic 
patients on weekly oral (oral BPs; n=3), or annual (>3yr) intravenous (iv BPs; n=3), 
bisphosphonates. (E) Plots of Vδ2(+) T cells from four infant thymuses (4-22-mths old). % of 
gated cells is indicated. 
Fig. 3. Vδ2-profiles polarize towards two dominant phenotypes. (A) Number of differentially 
expressed genes (≥2 fold difference and P < 0.05) between Vδ2(+) subsets. Multiple 
comparison tests were with False Discovery Rate (FDR) Benjamini-Hochberg P-value 
correction. (B) Average probability state model (GemstoneTM software) for CD28, CD27, 
CD16, CD45RA and CD11a on Vδ2(+)CD3(+) cells (n=63). Lines show average relative 
intensity of marker along a cumulative progression axis (x-axis). (C) Differentially expressed 
immune-related genes with ≥ 2-fold expression difference (P < 0.05) between γδ(28+) and 
γδ(16+) subsets. Dark shaded bars indicate in which subset gene expression is highest. 
Fig. 4. Demarcation of Vδ2(+) T cell phenotypes by CCR6 and CX3CR1. (A) Representative 
plots (left) and summary charts (right) showing (A) CCR6 and CX3CR1 on γδ(28+) and γδ(16+) T 
cells in healthy individuals (n=12), gating CCR6(+) γδ(28+) cells, CX3CR1(+) γδ(28+) cells, and 
CX3CR1(+) γδ(16+) cells. Subsets from (A), further stained for intracellular Perforin and 
Granzyme B (B), and Granzyme K and Granzyme B (C), or surface CCR2 and CCR5, 
following 4h PMA/Ionomycin stimulation (n=6-9). (E) MFI for IL-18Rα for subsets described 
in (A) (n=5). (F) Plots from four infant thymuses (4-22-mths old) for CCR6, CX3CR1, and 
intracellular Granzyme K and Granzyme B. (G) CCR6 and intracellular IL-17A expression in 
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Vδ2(+) and Vδ2(-) (predominantly αβ T cell) subsets from blood (n=2). (H) MFI for CD161 for 
Vδ2(+) subsets described in (A) (n=6). Mean values with error bars (s.d.). Multiple 
comparisons using one-way ANOVA with Tukey’s post-test *P < .05, **P < .01, ***P < .001, 
****P < .0001. 
Fig. 5. Distinct Vδ2-profiles display distinct cytotoxic effector potentials. (A) Fold-change in 
Vδ2(+) cells as % of CD3(+) cells 7-days after stimulation of PBMC with zoledronate (1µM) & 
IL-2 (100U/mL), comparing Vδ2-profiles #1 and #2 (n=10) with #5 and #6 (n=4). (B) 
Representative plots and summary MFIs (n=6) for intracellular Granzyme B, Granzyme K, 
and Granulysin from sorted Vδ2(+) cells from Vδ2-profiles #1 or #6, after 4h stimulation with 
PMA/ionomycin. (C) Chart showing % apoptosis of tumour lines after 4h co-culture with 
sorted Vδ2(+) T cells (Vδ2-profiles #1 or #6) from PBMC cultures stimulated for 12-days with 
1nM HMB-PP & 100U/mL IL-2. Effector:target ratios were 5:1. Error bars are s.d. (D-F) Charts 
showing % apoptosis of PI-9(+) HCT-116 (D), MOLT-4 (E), or DAUDI (F) cells after 4h co-
culture with sorted and activated (1nM HMB-PP and 100U/mL IL-2) Vδ2(+) T cells from Vδ2-
profiles #1 or #6 (n=3) ex vivo. Pre-treatment (16h) of Vδ2(+) cells with 100µM nafamostat 
mesylate (NM) was used to inhibit Granzyme K (D and E). Granzyme B was inhibited by 
100µM Z-AAD (E). Rituximab (anti-CD20 mAb) was included to induce antibody-dependent 
cellular cytotoxicity (F). Effector:target ratios were 5:1. Error bars are s.d. Differences 
compared with two-tailed, unpaired student’s t-tests;  *P < .05, **P < .01 and ***P < .001. 
